Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients. Many ARIA events ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

FIRST ON FOX: A new book sounding the alarm about corruption in California spends a chapter focusing on Gov. Gavin Newsom’s history with a nonprofit organization that the authors say served as a ...

Fed's tools, goals under the microscope as US House task force gets underway FILE PHOTO: An eagle tops the U.S. Federal Reserve building's facade in Washington · Reuters Bo Erickson and Ann Saphir ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. Our independent committee said last year that the ...

Formula One’s last cars of this generation have mainly converged on one solution which had a wide variety of design options on show at the beginning of this regulatory era. The sidepods on all ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...

But some experts say the side effects of the drug called donanemab may outweigh its benefits. It was given the green light by UK drug regulators, the Medicines and Healthcare Products Regulatory ...